Gines Diego Miralles

CIK: 0001773413

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ARTV

Artiva Biotherapeutics, Inc.

Officer

CTNM

Contineum Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ARTV
Artiva Biotherapeutics, Inc.
Sep 9, 2026
Award(A)
Direct
45K shares-
CTNM
Contineum Therapeutics, Inc.
Jun 26, 2026
Award(A)
Stock Option (right to buy)
Direct
19K shares-
ARTV
Artiva Biotherapeutics, Inc.
May 18, 2026
Award(A)
Direct
77.5K shares-
CTNM
Contineum Therapeutics, Inc.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
14.8K shares-
ARTV
Artiva Biotherapeutics, Inc.
Jun 24, 2025
Award(A)
Director Stock Option (Right to Buy)
Direct
13.8K shares-
CTNM
Contineum Therapeutics, Inc.
Mar 14, 2025
Award(A)
Stock Option (right to buy)
Direct
29.5K shares-

		Type	Shares	Price		Ownership
Sep 9, 2026	ARTV Artiva Biotherapeutics, Inc.	Award(A)	45,000	-	$0	Direct
Jun 26, 2026	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	19,000	-	-	Direct
May 18, 2026	ARTV Artiva Biotherapeutics, Inc.	Award(A)	77,500	-	$0	Direct
Jun 26, 2025	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	14,750	-	-	Direct
Jun 24, 2025	ARTV Artiva Biotherapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	13,750	-	-	Direct
Mar 14, 2025	CTNM Contineum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	29,500	-	-	Direct

1-6 of 6 transactions

About Miralles Gines Diego

Miralles Gines Diego (SEC CIK 0001773413) files insider reports with the SEC as President & Head of R&D of Artiva Biotherapeutics, Inc. (ARTV) and Director of Contineum Therapeutics, Inc. (CTNM).

Signal8 holds 7 ownership filings by Miralles Gines Diego (1 Form 3, 6 Form 4), filed between Mar 17, 2025 and Sep 11, 2026. Those filings report 6 transactions, from Mar 14, 2025 to Sep 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Miralles Gines Diego's filings is in SAN DIEGO, CA.

Recent filings by Miralles Gines Diego

Sep 9, 2026: Grant or award of ARTV shares (Form 4, code A).
Jun 26, 2026: Grant or award of CTNM derivative securities (Form 4, code A).
May 18, 2026: Grant or award of ARTV shares (Form 4, code A).
Jun 26, 2025: Grant or award of CTNM derivative securities (Form 4, code A).
Jun 24, 2025: Grant or award of ARTV derivative securities (Form 4, code A).

Other insiders filing for Artiva Biotherapeutics, Inc. (ARTV)

Aslan Fred, Chief Executive Officer
Horan Christopher, Chief Tech Operations Officer
Bush Jennifer, COO, CLO, Compliance Officer
Banerjee Subhashis, Chief Medical Officer
RA CAPITAL MANAGEMENT, L.P., Director
Stoppel Laura, Director

How to read Form 4 transaction codes